SAGE News and Press, Sage Therapeutics Inc. From 04/24/24

2024-04-24 09:46:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2024-04-24 08:03:47 ET More on Biogen Biogen Inc. (BIIB) Stifel 2024 Virtual CNS Days (Transcript) Biogen Inc. (BIIB) TD Cowen 44th Annual Health Care Conference - (Transcript) Biogen's Q4 Earnings Disappoint Amidst Strategic Challenges (Rating Downgrade) Bio...

2024-04-18 16:56:16 ET Gainers: Travere Therapeutics ( TVTX ) +6% . Sabre Corporation ( SABR ) +5% . Nextracker  ( NXT ) +3% . Cipher Mining  ( CIFR ) +3% . BioCryst Pharmaceuticals ( BCRX ) +3% . Losers: Avidit...

2024-04-18 08:00:00 ET Summary Sage Therapeutics' investigational drug for Parkinson's disease, dalzanemdor, failed in a Phase 2 trial, leading to a 20% drop in the stock. Despite FDA approvals for PPD treatments, Sage's revenue remains low, impacting financial stability and marke...

A look at the top 10 most actives in the United States SiNtx Technologies Inc. (SINT) rose 62.9% to $0.0373 on volume of 466,310,671 shares INVO BioScience Inc. (INVO) rose 139.5% to $1.82 on volume of 225,666,770 shares PROSHARES TRUST (SQQQ) rose 3.7% to $11.86 on volume of 167,545,988 ...

2024-04-17 12:30:03 ET Goldman Sachs analyst issues NEUTRAL recommendation for SAGE on April 17, 2024 10:07AM ET. The previous analyst recommendation was Neutral. SAGE was trading at $12.11 at issue of the analyst recommendation. The overall analyst consensus : BUY. ...

2024-04-17 12:00:02 ET Joon Lee from Truist Financial issued a price target of $22.00 for SAGE on 2024-04-17 10:06:00. The adjusted price target was set to $22.00. At the time of the announcement, SAGE was trading at $12.3199. The overall price target consensus is at $64...

2024-04-17 11:30:02 ET Raymond James analyst issues MARKET PERFORM recommendation for SAGE on April 17, 2024 10:05AM ET. The previous analyst recommendation was Market Perform. SAGE was trading at $12.3199 at issue of the analyst recommendation. The overall analyst conse...

2024-04-17 11:14:48 ET More on Sage Therapeutics SAGE Therapeutics, Inc. (SAGE) Q4 2023 Earnings Call Transcript Sage Therapeutics, Inc. 2023 Q4 - Results - Earnings Call Presentation Sizing Up Sage Therapeutics Sage drops after mid-stage setback for Parkinso...

2024-04-17 10:00:55 ET More on Health Care Select Sector SPDR XLV: Fundamentals Don't Support Overweighting Health Care XLV: Low-Cost Exposure To A Defensive Sector, While Achieving Strong Performance Short interest in S&P 500 health stocks rises, Moderna among m...